University of North Carolina, Chapel Hill
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).
University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.
University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Top-decile sponsor footprint
University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,109 total, page 3 of 23
Food as Medicine for HIV and Diabetes
NCT05026723
Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
NCT06057714
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
NCT04875052
Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
NCT04328337
Orthognathic Speech Pathology: Phonetic Contrasts of Patients With Dental Discrepancies Pre- and Post-Treatment Analyses
NCT04117360
Synergistic Activity of Human Milk Nutrients and Infant Cognition
NCT03838536
Pharmacokinetics of Off Label Pediatric Medications
NCT01286519
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
NCT00807482
Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program
NCT07534254
Omega-3 Supplementation for Pediatric Migraine
NCT06899074
Collaborate and Leverage Evidence in African American Rural Network
NCT06730633
Long-term Outcomes of Complex Conversion Total Hip Arthroplasty
NCT06533020
Perineal Massage for Pessary Examinations
NCT06416982
Anifrolumab for Hidradenitis Suppurativa
NCT06374212
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06352073
Forging New Paths: Building Interventions to Treat Criminogenic Needs in Community Based Mental Health Settings
NCT06290648
Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
NCT06158113
CommunityRx-Cardiovascular Disease
NCT06264726
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction
NCT06204432
Improving the Health of Parents and Their Adolescent and Transition-age Youth With Intellectual and Developmental Disabilities
NCT05986305
PROs Following Low-dose Irradiation for Osteoarthritis
NCT05705947
AF at Home: A Virtual Education Program for Patients With Atrial Fibrillation (AF)
NCT05810896
The Immune Directed Individualized Elimination Therapy (iDIET) Study
NCT05543512
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
NCT05890274
Water From Bottles to Establish Strong Teeth
NCT04893681
Food As MedicinE for Diabetes
NCT04828785
Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis
NCT04262167
NFL LONG Prospective Study
NCT04263337
Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk
NCT04063709
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
NCT03554356
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
NCT03417297
Risk Factors and Biomarkers for Diagnosis and Treatment of EoE
NCT01988285
Study of COPD Subgroups and Biomarkers
NCT01969344
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
NCT00804583
Gene Modifiers of Cystic Fibrosis Lung Disease
NCT00037765
Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities
NCT06915428
Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in Adults With Chronic Cough
NCT07566117
Marine Lipids Ease Painful TMD
NCT07437313
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
NCT07588568
Comparing the Effects of Front-of-Package Labeling Schemes in Indonesia
NCT07526584
Teen Vulnerability to Irritability: Brain and Estrogen Changes
NCT07544966
Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)
NCT07600190
UNC Cashew Sublingual Immunotherapy
NCT07170540
Integrating New Skills Into Diabetes Education With CGM
NCT07463209
Reducing Post-Operative Opioid Prescribing in Southeastern North Carolina
NCT07566182
Mast Cell Treatment in Post-tick Bite Illness (PTBI)
NCT07526558
AI Tool to Reduce Clinician Documentation Burden
NCT07498582
Adolescent Mental Health Parenting Program for Child-Adult Relationship Enhancement
NCT07303062
Mobile Alcohol Use Intervention
NCT07126613
Testing Non-nutritive Sweetener Labels in Chile
NCT06842693
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 111 |
| Phase 2 | 92 |
| Phase 3 | 13 |
| Phase 4 | 56 |
Therapeutic Areas
What is open in the University of North Carolina, Chapel Hill pipeline
108 recruiting of 1,109 indexed (10% open); 881 completed (79%).
Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Obesity (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of North Carolina, Chapel Hill: open-pipeline peers nationwide
Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,109 trials (± recruiting share)
- University of Florida · 1,106 trials · 15% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Ohio University · 10% recruiting · 51 trials
Related
What to do with this University of North Carolina, Chapel Hill page
1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.
- 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets.Report a data error.